Full metadata record
DC FieldValueLanguage
dc.creatorPersson, M.L. (Mika L.)-
dc.creatorDouglas, A.M. (Alicia M.)-
dc.creatorAlvaro, F. (Frank)-
dc.creatorFaridi, P. (Pouya)-
dc.creatorLarsen, M.R. (Martin R.)-
dc.creatorAlonso-Roldán, M.M. (Marta María)-
dc.creatorVitanza, N.A. (Nicholas A.)-
dc.creatorDun, M.D. (Matthew D.)-
dc.identifier.citationPersson, M. L.; Douglas, A. M.; Alvaro, F.; et al. "The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies". Neuro-oncology. 24 (9), 2022, 1408 - 1422es
dc.description.abstractDiffuse midline glioma (DMG), including those of the brainstem (diffuse intrinsic pontine glioma), are pediatric tumors of the central nervous system (CNS). Recognized as the most lethal of all childhood cancers, palliative radiotherapy remains the only proven treatment option, however, even for those that respond, survival is only temporarily extended. DMG harbor an immunologically cold tumor microenvironment (TME) with few infiltrating immune cells. The mechanisms underpinning the cold TME are not well understood. Low expression levels of immune checkpoint proteins, including PD-1, PD-L1, and CTLA-4, are recurring features of DMG and likely contribute to the lack of response to immune checkpoint inhibitors (ICIs). The unique epigenetic signatures (including stem cell-like methylation patterns), a low tumor mutational burden, and recurring somatic mutations (H3K27M, TP53, ACVR1, MYC, and PIK3CA), possibly play a role in the reduced efficacy of traditional immunotherapies. Therefore, to circumvent the lack of efficacy thus far seen for the use of ICIs, adoptive cell transfer (including chimeric antigen receptor T cells) and the use of oncolytic viruses, are currently being evaluated for the treatment of DMG. It remains an absolute imperative that we improve our understanding of DMG's intrinsic and TME features if patients are to realize the potential benefits offered by these sophisticated treatments. Herein, we summarize the limitations of immunotherapeutic approaches, highlight the emerging safety and clinical efficacy shown for sophisticated cell-based therapies, as well as the evolving knowledge underpinning the DMG-immune axis, to guide the development of immunotherapies that we hope will improve outcomes.-
dc.description.sponsorshipM.D.D. is supported by an NHMRC Investigator Grant— GNT1173892. The contents of the published material are solely the responsibility of the research institutions involved or individual authors and do not reflect the views of NHMRC. M.D.D. is a recipient of a ChadTough New Investigator Grant 2020-2021. M.L.P. is supported by the RUN DIPG International HDR Scholarship. This project was supported by the Little Legs Foundation in partnership with the Charlie Teo Foundation, RUN DIPG, Strategic Group, Blackjack Foundation, Vinva Foundation, Edie’s Kindness Project, Hirsch Family Funderpants, Yuvaan Tiwari Foundation via the Pacific Pediatric Neuro- Oncology Consortium Foundation, Kiriwina Investments via the Hunter Medical Research Institute, Cure Starts Now, DIPG Collaborative, Fight on the Beaches, Tour de Cure, Michael Mosier Defeat DIPG Foundation, and the Liv Like A Unicorn Foundation. P.F. is supported by the Victorian Department of Health and Human Services acting through the Victorian Cancer Agency.-
dc.subjectDiffuse intrinsic pontine glioma (DIPG)-
dc.subjectDiffuse midline glioma (DMG)-
dc.subjectPediatric high-grade glioma (HGG)-
dc.subjectCar t-cells-
dc.subjectPotential therapeutic target-
dc.subjectPediatric high-grade-
dc.subjectH3.3K27M mutation-
dc.titleThe intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies-
dc.description.noteThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.-

Files in This Item:
2.73 MB
Adobe PDF

Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.